Hanbeta® (bevacizumab) is a biosimilar to Avastin® (bevacizumab) developed by Fosun Pharma, and is indicated for the treatment of metastatic colorectal cancer, advanced, metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, hepatocellular carcinoma, etc.